On May 14, 2020, BioSig Technologies announced that an article titled, “The IMPDH inhibitor merimepodib provided in combination with the adenosine analogue remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro” was published by F1000 Research, an online peer-reviewed life sciences journal publishing program in biology and medicine, while it is undergoing peer review.

The article highlights pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch.